Global Nuclear Medicine Diagnostics Market (SPECT and PET ) - Analysis and Forecasts (2016 - 2021)

  • ID: 3784826
  • Report
  • Region: Global
  • 127 pages
  • Mordor Intelligence
1 of 4


  • Bracco Pharma
  • Cardinal Health
  • Fujifilm Holding Cor
  • GE Healthcare
  • IBA Group
  • Lantheus Medical Imaging
  • MORE
The Global Nuclear Medicine Market is expected to reach USD 17,600 million by the end of 2019 growing at a CAGR of around 12.29% from 2014 to 2019. Nuclear Medicine utilizes the radioisotope for application in diagnosis and treatment of diseases. The drugs containing radionuclides are said to be Radiopharmaceuticals. The uses in Radiological imaging include Magnetic Resonance Imaging (MRI), Computerized tomography (CT), Positron Emission Tomography (PET) and Single Proton Emission Tomography (SPECT).

The Nuclear Medicine for diagnostic purposes have gained a huge popularity all round the world. There have been increased use of SPECT, PET, CT, MRI for diagnosis of cardiac diseases, Brain diseases, Cancer and many others. Nuclear medicine is being used for therapeutic purposes for treatment of Alzheimer’s disease, coronary heart diseases, bone metastasis and many other cancers. Advancement in Diagnostic imaging is bringing in more use of Nuclear medicine. Nuclear Cardiology have gained a great popularity in North America. Nuclear Medicine for therapeutic purposes is being used for treatment of cancers, different medical conditions affecting thyroid gland, and scar - tissue removal.

The increasing incidence and prevalence of Cancer and cardiac Ailments, increasing applications of SPECT and PET with advancement of technology and growing awareness amongst physicians and public awareness for better healthcare are key factors driving the growth of Nuclear medicine market. However, Short half-life of Radiopharmaceuticals, high capital investment required for development, stringent regulatory guidelines are factors turning out to be restraints for this market.

The global Nuclear Medicine Market have been segmented based on, type and application. The segmentation based on type of Product have been segmented based on diagnostic market and therapeutic market, wherein, the Diagnostics market have been further subdivided into SPECT radioisotopes that include Technetium-993, Thallium-201, Iodine-123, Gallium and PET radioisotopes that include Rubidium-82, Flourine-18 and the therapeutics category have been segmented into Alpha emitters (Radium-223), Beta Emitters(includes Iodine-131, Samarium-153, Lutetium-177, Yttrium-90) and Brachytherapy (includes iodine-125, Cesium-131, Palladium-103, & Iridium-192). The segmentation based on application have been similarly subdivided based on diagnostic and therapeutic application. The Diagnostic application includes the application of SPECT and PET in Cardiology, Neurology, Oncology and others. The therapeutic applications includes application in Oncology, Thyroid, Endocrinology and various other therapeutic areas.

The global nuclear medicine market have been geographically segmented into North America (includes United States, Canada, and Mexico), Europe (includes Germany, UK, France, Italy Spain, Portugal, Scandinavia and Benelux), Asia-Pacific (includes China, Japan, India, Australia & New Zealand, South Korea and Rest of Asia Pacific), Middle East and Africa (includes GCC, Egypt, Morocco, Algeria and South Africa), and Latin America (includes Brazil, Argentina and Rest of South America). Due to high technological advancement coupled with developed economy, the North America has the largest market share followed by Europe and Asia-Pacific.

Currently, the segment of diagnostics holds the largest share in Nuclear Medicine Market in which again SPECT has the largest share. In the segmentation based on type, the Beta Emitters hold the largest share. The increasing imaging technologies, potential radioisotopes in pipeline, increasing neurological applications and cyclotron based production are becoming key opportunities for growth of Nuclear Medicine Market. The Key Players in this Nuclear Medicine market are Mallinckrodt, Lantheus Medical Imaging, IBA Group, Triad Isotope, Siemens Healthcare, NTP Radioisotopes, Bracco Pharma, Cambridge Isotope Laboratories, Cardinal Health, GE Healthcare, Nordion, Inc., Taiya Nippon Sanso Corporation.

Key deliverables of the study

- Market Definition for the specified topic along with identification of key drivers and restraints for the market.
- Market analysis for the Global Nuclear Medicine Market in Healthcare Industry, with region specific assessments and competition analysis on a global and regional scale.
- Identification of factors instrumental in changing the market scenarios, rising prospective opportunities and identification of key companies which can influence the market on a global and regional scale.
- Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market shares.
- Identification and analysis of the Macro and Micro factors that affect the Global Nuclear Medicine Market in Healthcare Industry on both global and regional scale.
- A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

Please note: As this product is updated at the time of order, dispatch will be 72 hours from the date the order and full payment is received
Note: Product cover images may vary from those shown
2 of 4


  • Bracco Pharma
  • Cardinal Health
  • Fujifilm Holding Cor
  • GE Healthcare
  • IBA Group
  • Lantheus Medical Imaging
  • MORE
  • Introduction
  • Study deliverables
  • Market Definition
  • Sizing Units
  • Base Currency
  • Review and Forecast period
  • General Study Assumptions
  • Research Methodology
  • Introduction
  • Analysis Methodology
  • Econometric Forecast
  • Research Assumptions
  • Executive Summary
  • Key Inferences
  • Market Overview and Industry
  • Current Market Senario
  • Nuclear Medicine Applications
  • Technology Overview
  • New Developments
  • Industry Value chain analysis
  • Porter's Five Forces
  • Bargaining Power of Suppliers
  • Bargaining Power of Consumers
  • Threat to new entrants
  • Threat to substitute products and services
  • Competitive Rivalry within the industry
  • Drivers, Restraints, Opportunities
  • Market Drivers
  • Increasing incidents of Cancer and Cardiac Ailments
  • Increasing SPECT and PET applications
  • Growing awareness amongst Physicians and Public usage of Advanced healthcare facilities
  • Market Restraints
  • Short half-life of Radiopharmaceuticals
  • High Capital Investment
  • Regulatory Guidelines
  • Opportunities
  • Increasing Imaging Technologies
  • Potential Radioisotopes in Pipeline
  • Increasing Neurological Applications
  • Cyclotron Based Production
  • Threats
  • Shutdown of Nuclear Reactors
  • Global Nuclear Medicine Market Segmentation
  • Nuclear Medicine Market, by Type of Product
  • Diagnostic Market
  • SPECT Radioisotopes
  • Technetium-99m (TC-99m)
  • Thallium-201 (Tl-201)
  • Iodine (I-123)
  • Gallium-67 (Ga-67)
  • Others
  • PET Radioisotopes
  • Rubidium-82 (Rb-82)
  • Fluorine-18 (F-18)
  • Others
  • Therapeutics Market
  • Alpha Emitters
  • Radium-223 (Ra-223)
  • Beta Emitters
  • Iodine-131 (I-131)
  • Samarium-153 (Sm-153)
  • Rhenium-186 (Re-186)
  • Lutetium-177 (Lu-177)
  • Yttrium-90 (Y-90)
  • Others
  • Brachytherapy
  • Iodine-125 (I-125)
  • Cesium-131 (Cs-131)
  • Palladium-103
  • Iridium-192
  • Others
  • Nuclear Medicine Market, by Application
  • Diagnostics
  • PET
  • Cardiology
  • Neurology
  • Oncology
  • Others
  • Cardiology
  • Neurology
  • Oncology
  • Others
  • Therapeutics
  • Oncology
  • Thyroid
  • Endocrinology
  • Others
  • Market segmentation by Geography - Regional Share and forecast
  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain & Portugal
  • Scandinavia
  • Bebelux
  • Asia-Pacific (APAC)
  • China
  • Japan
  • India
  • Australia & Newzealand
  • South Korea
  • Rest of APAC
  • Middle-East and Africa (MEA)
  • GCC
  • Egypt
  • Algeria
  • Morocco
  • South Africa
  • Rest of MEA
  • South America
  • Brazil
  • Argentina
  • Rest of South America
  • Competitive Landscape
  • Merger and acquisition analysis
  • New Product Launches
  • Agreements, Collaborations and Parterships
  • Key Vendor Analysis
  • Mallinckrodt
  • Lantheus Medical Imaging
  • IBA Group
  • Triad Isotope
  • Siemens Healthcare
  • NTP Radioisotopes
  • Bracco Pharma
  • Cambridge Isotope Laboratories, Inc.
  • Cardinal Health, Inc.
  • GE Healthcare
  • Nordion, Inc.
  • Taiya Nippon Sanso Corporation
  • Fujifilm Holding Corporation
  • Eczacibasi-Monrol
  • Isotec, Inc.
  • Petnet Solutions, Inc.
  • Analyst outlook for Investment opportunities
  • Future Outlook of the market
Note: Product cover images may vary from those shown
3 of 4


4 of 4
Lantheus Medical Imaging
IBA Group
Triad Isotope
Siemens Healthcare
NTP Radioisotopes
Bracco Pharma
Cambridge Isotope Laboratories
Cardinal Health
GE Healthcare
Taiya Nippon Sanso Corporation
Fujifilm Holding Cor
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown